| FDA review agrees with SHARP data: Vytorin up for expanded use in CKD - TheHeart.Org |
|
|
TheHeart.Org Rockville, MD - The Food and Drug Administration (FDA) has posted their review of the Study of Heart and Renal Protection (SHARP) with Vytorin (Merck/Schering-Plough), a combination of ezetimibe and simvastatin, stating that the drug is effective in |